{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T07:52:16Z","timestamp":1719733936763},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"Suppl1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"abstract":"<jats:p>Imipenem combined with beta-lactamase inhibitor relebactam (IMI\/REL) has an extensive bactericidal activity against Gram-negative pathogens producing class A or class C beta-lactamases, not active against class B and class D. The phase 3 clinical trial (RESTORE-IMI-2), double-blind, randomized, evaluated IMI\/REL vs. piperacillin-tazobactam (PIP\/TAZ) for treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), demonstrated non-inferiority at all-cause mortality at 28 days (15.9% vs 21.3%), favorable clinical response at 7-14 days end of treatment (61% vs 59.8%) and with minor serious adverse effects (26.7% vs 32%). IMI\/REL is a therapeutic option in HAP and VAP at approved dosage imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg once every 6h, by an IV infusion over 30 min.<\/jats:p>","DOI":"10.37201\/req\/s01.11.2022","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T07:26:27Z","timestamp":1651303587000},"page":"46-49","source":"Crossref","is-referenced-by-count":2,"title":["New evidence in severe pneumonia: imipenem\/ cilastatin\/relebactam"],"prefix":"10.37201","volume":"35","author":[{"given":"Rosa M\u00aa","family":"Gir\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar","family":"G\u00f3mez-Punter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"23328","published-online":{"date-parts":[[2022,4,22]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:46:50Z","timestamp":1651650410000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-2022-april-11-3\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":0,"journal-issue":{"issue":"Suppl1","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,4,22]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/s01.11.2022","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]}}}